Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin01:26

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

897
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
897
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action01:17

Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action

2.4K
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
2.4K
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:29

Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

750
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
750
Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

443
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
443
Depolarizing Blockers: Mechanism of Action01:28

Depolarizing Blockers: Mechanism of Action

2.2K
Depolarizing blockers act on skeletal muscle fibers' membranes and induce their depolarization. Most depolarizing blockers have two quaternary N+ atoms that bind the nicotinic acetylcholine receptors and cause neuromuscular blockade within minutes.
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because...
2.2K
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics01:11

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics

596
All neuromuscular blocking agents are injected intravenously because they are poorly absorbed from the GI tract. Rapid onset is achieved with intravenous administration, although absorption is also adequate from an intramuscular injection. Since these agents are highly ionized, they do not readily penetrate cell membranes or cross the blood-brain barrier.
Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more...
596

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Decoding the CSF Proteomic Signature of Idiopathic Normal Pressure Hydrocephalus: A Systematic Review.

Molecules (Basel, Switzerland)·2026
Same author

Long-term use of rozanolixizumab in generalised myasthenia gravis: final pooled analysis of the phase III MycarinG study and two open-label extensions.

Therapeutic advances in neurological disorders·2026
Same author

Longitudinal Dynamics of Polyglutamine-Expanded ATXN3 in Biofluids of Spinocerebellar Ataxia Type 3.

Movement disorders : official journal of the Movement Disorder Society·2026
Same author

Discovery of a mutation-containing circRNA in polyglutamine disease through systematic analysis of RNAs with CAG repeats.

RNA biology·2026
Same author

Cyclodextrin-Based Nanocarriers for 5-Fluorouracil: Cholesteryl Modification Enhances Antitumor Activity Against Colorectal Cancer Cells.

International journal of nanomedicine·2026
Same author

Deep brain stimulation and sleep in Parkinson's disease: unresolved questions and a decade of missing research.

Parkinsonism & related disorders·2026

Related Experiment Video

Updated: Nov 10, 2025

A High-throughput-compatible FRET-based Platform for Identification and Characterization of Botulinum Neurotoxin Light Chain Modulators
10:30

A High-throughput-compatible FRET-based Platform for Identification and Characterization of Botulinum Neurotoxin Light Chain Modulators

Published on: December 27, 2013

5.5K

Botulinum toxin type-A preparations are not the same medications - basic science (Part 1).

Halina Car1, Andrzej Bogucki2, Marcin Bonikowski3

  • 1Deprtment of Experimental Pharmacology, Medical University of Bialystok, Poland.

Neurologia I Neurochirurgia Polska
|April 2, 2021
PubMed
Summary

This review compares Botulinum neurotoxin type A (BoNT/A) formulations, highlighting differences in molecular structure, action, spread, and immunogenicity. Understanding these distinctions is crucial for clinical application and bioequivalence discussions.

Keywords:
abobotulinumtoxinAbotulinum toxin A formulationincobotulinumtoxinAonabotulinumtoxinApharmacological similarities and differencies

More Related Videos

A High Content Imaging Assay for Identification of Botulinum Neurotoxin Inhibitors
14:10

A High Content Imaging Assay for Identification of Botulinum Neurotoxin Inhibitors

Published on: November 14, 2014

8.8K
Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays
12:25

Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays

Published on: March 3, 2014

16.3K

Related Experiment Videos

Last Updated: Nov 10, 2025

A High-throughput-compatible FRET-based Platform for Identification and Characterization of Botulinum Neurotoxin Light Chain Modulators
10:30

A High-throughput-compatible FRET-based Platform for Identification and Characterization of Botulinum Neurotoxin Light Chain Modulators

Published on: December 27, 2013

5.5K
A High Content Imaging Assay for Identification of Botulinum Neurotoxin Inhibitors
14:10

A High Content Imaging Assay for Identification of Botulinum Neurotoxin Inhibitors

Published on: November 14, 2014

8.8K
Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays
12:25

Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays

Published on: March 3, 2014

16.3K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Biochemistry

Background:

  • Botulinum neurotoxin type A (BoNT/A) formulations are extensively utilized in clinical settings.
  • Despite a shared mechanism of blocking acetylcholine release, significant structural and pharmacological variations exist among BoNT/A products.
  • The concept of bioequivalence for BoNT/A has been a topic of discussion since their clinical introduction.

Purpose of the Study:

  • To provide an updated review of studies concerning different BoNT/A formulations.
  • To compare key characteristics including molecular structure, mechanisms of action, diffusion, spread, immunogenicity, and dose equivalence.
  • To inform clinical practice and bioequivalence assessments by detailing the similarities and differences between major BoNT/A products.

Main Methods:

  • Literature review and comparative analysis of existing scientific studies.
  • Examination of data on molecular structure and pharmacological properties.
  • Assessment of clinical data related to diffusion, spread, immunogenicity, and dose equivalence.

Main Results:

  • Detailed comparison of onabotulinumtoxinA, abobotulinumtoxinA, and incobotulinumtoxinA.
  • Identification of specific differences in protein structure, complex formation, and biological activity.
  • Analysis of variations in diffusion patterns, potential for spread, and immunogenic responses.

Conclusions:

  • Significant differences exist between BoNT/A formulations beyond their shared mechanism of action.
  • These variations impact clinical outcomes, dosing, and the potential for immunogenicity.
  • A thorough understanding of these distinctions is essential for appropriate clinical selection and bioequivalence evaluation.